- Home
- AMAL vs VIR Comparison
AMAL vs VIR Comparison
Compare AMAL & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMAL
- VIR
- Stock Information
- Founded
- AMAL 1923
- VIR 2016
- Country
- AMAL United States
- VIR United States
- Employees
- AMAL N/A
- VIR N/A
- Industry
- AMAL Commercial Banks
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- AMAL Finance
- VIR Health Care
- Exchange
- AMAL Nasdaq
- VIR Nasdaq
- Market Cap
- AMAL 867.2M
- VIR 844.9M
- IPO Year
- AMAL 2018
- VIR 2019
- Fundamental
- Price
- AMAL $30.22
- VIR $4.94
- Analyst Decision
- AMAL Buy
- VIR Strong Buy
- Analyst Count
- AMAL 3
- VIR 7
- Target Price
- AMAL $36.50
- VIR $32.86
- AVG Volume (30 Days)
- AMAL 161.7K
- VIR 1.6M
- Earning Date
- AMAL 07-24-2025
- VIR 05-07-2025
- Dividend Yield
- AMAL 1.85%
- VIR N/A
- EPS Growth
- AMAL 9.81
- VIR N/A
- EPS
- AMAL 3.36
- VIR N/A
- Revenue
- AMAL $303,970,000.00
- VIR $20,861,000.00
- Revenue This Year
- AMAL $11.72
- VIR N/A
- Revenue Next Year
- AMAL $12.48
- VIR $15.32
- P/E Ratio
- AMAL $8.99
- VIR N/A
- Revenue Growth
- AMAL 7.13
- VIR N/A
- 52 Week Low
- AMAL $24.02
- VIR $4.32
- 52 Week High
- AMAL $38.19
- VIR $14.45
- Technical
- Relative Strength Index (RSI)
- AMAL 53.57
- VIR 45.01
- Support Level
- AMAL $29.68
- VIR $4.37
- Resistance Level
- AMAL $30.90
- VIR $5.24
- Average True Range (ATR)
- AMAL 0.84
- VIR 0.32
- MACD
- AMAL -0.11
- VIR 0.07
- Stochastic Oscillator
- AMAL 40.33
- VIR 49.60
About AMAL Amalgamated Financial Corp. (DE)
Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers various products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management and trust and custody services.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.